Detailed Study of the Metastatic Colorectal Cancer - Pipeline Review, H2 2016

Metastatic Colorectal Cancer - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Metastatic Colorectal Cancer (Oncology) pipeline landscape.

Metastatic colorectal cancer is a cancer that spread to other parts of the body. When colon or rectal cancer spreads, it most often spreads to the liver. Sometimes it spreads to the lungs, bones, or other organs in the body. The most common symptoms are belly pain, especially gas pains, cramps, or a feeling of fullness, blood in stool or very dark stools. Treatment of metastatic colorectal cancer includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

This report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 59, 34, 4, 15, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 4 molecules, respectively.Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

To access full report with TOC, please visit Metastatic Colorectal Cancer - Pipeline Review, H2 2016

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3SBio Inc AB Science SA AbbVie Inc Advenchen Laboratories LLC Alchemia Ltd Apexigen Inc ArQule Inc Array BioPharma Inc Asana BioSciences LLC Astex Pharmaceuticals Inc AstraZeneca Plc Bavarian Nordic A/S Bayer AG Biocon Ltd Bionomics Ltd Bionovis SA Biothera Pharmaceutical Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Burzynski Research Institute Inc Celgene Corp Celltrion Inc Cipla Ltd Coherus BioSciences Inc Cornerstone Pharmaceuticals Inc DanDrit Biotech A/S Dr. Reddy's Laboratories Ltd EirGenix Inc. Eisai Co Ltd Eli Lilly and Company EnGeneIC Ltd Etubics Corp Exelixis Inc F. Hoffmann-La Roche Ltd Gene Techno Science Co Ltd Genor BioPharma Co Ltd Genzyme Corp Gilead Sciences Inc GlaxoSmithKline Plc Glycotope GmbH Hemispherx Biopharma Inc Hutchison MediPharma Ltd Ignyta Inc Immodulon Therapeutics Ltd Immunomedics Inc Immunovative Therapies Ltd Karyopharm Therapeutics Inc Mabion SA Mabtech Limited mAbxience SA MacroGenics Inc MedImmune LLC Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Merus NV MolMed SpA Mologen AG Morphotek Inc Mycenax Biotech Inc Natco Pharma Ltd Nektar Therapeutics Nippon Kayaku Co Ltd Northwest Biotherapeutics Inc Novartis AG OBI Pharma Inc Oncobiologics Inc Oncolytics Biotech Inc OncoMed Pharmaceuticals Inc Ono Pharmaceutical Co Ltd Pfizer Inc Pharma Mar SA Pivot Pharmaceuticals Inc Precision Biologics Inc PsiOxus Therapeutics Ltd R Pharm Regeneron Pharmaceuticals Inc Richter Gedeon Nyrt Shanghai Henlius Biotech Co., Ltd. Shire Plc Sillajen Biotherapeutics Symphogen A/S Synermore Biologics Co Ltd Taiho Pharmaceutical Co Ltd TaiwanJ Pharmaceuticals Co Ltd Tocagen Inc Vaximm AG XBiotech Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###